TY - JOUR
T1 - A common antigenic motif recognized by naturally occurring human V H 5-51/V L 4-1 anti-tau antibodies with distinct functionalities
AU - Apetri, Adrian
AU - Crespo, Rosa
AU - Juraszek, Jarek
AU - Pascual, Gabriel
AU - Janson, Roosmarijn
AU - Zhu, Xueyong
AU - Zhang, Heng
AU - Keogh, Elissa
AU - Holland, Trevin
AU - Wadia, Jay
AU - Verveen, Hanneke
AU - Siregar, Berdien
AU - Mrosek, Michael
AU - Taggenbrock, Renske
AU - Ameijde, Jeroenvan
AU - Inganäs, Hanna
AU - van Winsen, Margot
AU - Koldijk, Martin H.
AU - Zuijdgeest, David
AU - Borgers, Marianne
AU - Dockx, Koen
AU - Stoop, Esther J. M.
AU - Yu, Wenli
AU - Brinkman-van der Linden, Els C.
AU - Ummenthum, Kimberley
AU - van Kolen, Kristof
AU - Mercken, Marc
AU - Steinbacher, Stefan
AU - de Marco, Donata
AU - Hoozemans, Jeroen J.
AU - Wilson, Ian A.
AU - Koudstaal, Wouter
AU - Goudsmit, Jaap
PY - 2018
Y1 - 2018
N2 - Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG + memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated V H 5-51/V L 4-1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of V H 5-51 and V L 4-1 recognizes a common Pro-X n -Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD.
AB - Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG + memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated V H 5-51/V L 4-1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of V H 5-51 and V L 4-1 recognizes a common Pro-X n -Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85058091008&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29855358
U2 - https://doi.org/10.1186/s40478-018-0543-z
DO - https://doi.org/10.1186/s40478-018-0543-z
M3 - Article
C2 - 29855358
SN - 2051-5960
VL - 6
SP - 43
JO - Acta Neuropathologica Communinications
JF - Acta Neuropathologica Communinications
IS - 1
M1 - 43
ER -